國立虎尾科技大學 |

Experimental and clinical evidence of the neuropathology of Parkinson's disease

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Experimental and clinical evidence of the neuropathology of Parkinson's disease/ Ahmed Draoui, Omar El Hiba, Arumugam R. Jayakumar, editors.
其他作者:	Jayakumar, Arumugam R.
出版者:	Hershey, Pennsylvania :IGI Global, : 2023.,
面頁冊數:	1 online resource (xxvii, 447 p.)
標題:	Parkinson's disease - Pathogenesis. -
電子資源:	http://services.igi-global.com/resolvedoi/resolve.aspx?doi=10.4018/978-1-6684-5156-4
ISBN:	9781668451571

Experimental and clinical evidence of the neuropathology of Parkinson's disease
Experimental and clinical evidence of the neuropathology of Parkinson's disease[electronic resource] /Ahmed Draoui, Omar El Hiba, Arumugam R. Jayakumar, editors. - Hershey, Pennsylvania :IGI Global,2023. - 1 online resource (xxvii, 447 p.)

Includes bibliographical references and index.

Preface -- Chapter 1. History and Epidemiology of Parkinson's Disease -- Chapter 1. Epidemiology of Parkinson's Disease: An Updated Overview -- Chapter 2. Sympatomatology and Diagnosis of Parkinson's Disease -- Chapter 2. Symptomatology and Clinical Features of Parkinson's Disease -- Chapter 3. Non-Motor Symptoms in Parkinson's Disease: The Other Side of the Disease -- Chapter 4. Diagnosing Methods of Parkinson's Disease: Revolutionary Techniques -- Chapter 5. Diagnostic Biomarkers of Parkinson's Disease -- Chapter 3. Neuropathology of Parkinson's Disease -- Chapter 6. Neuropathology of Parkinson's Disease: An Update of the Recent Findings -- Chapter 7. Clinical and Experimental Evidence of Cirrhosis-Related Parkinsonism -- Chapter 4. Etiologies and Risk Factors of Parkinson's Disease -- Chapter 8. Parkinson's Disease: Clinical Manifestations and Risk Factors -- Chapter 9. Sex Dimorphism and Parkinson's Disease: What We Learned -- Chapter10. An Overview of the Genetics of Parkinson's Disease -- Chapter 11. Pesticide Exposure as a Risk Factor for Parkinson's Disease -- Chapter 12. Impact of Hydrocarbon Exposure on the Risk of Parkinson's Disease -- Chapter 5. Management of Parkinson's Disease: Pharmacological and Non-Pharmacological Treatments -- Chapter 13. Pharmacological Treatments of Parkinson's Disease: Preventing and Curing Approaches -- Chapter 14. Parkinson's Disease Related to Food and Nutrition: WhatWe Learned -- Chapter 15. Chitosan and Its Derivatives as Potential Neuro-Protective Agents for the Treatment of Parkinson's Disease -- Chapter 16. Effects of Physical Activity on Pakinson's Disease Patients -- Chapter 17. Potential Role of Probiotics and Fecal Microbiota Transplantation in the Treatment of Parkinson's Disease -- Chapter 18. Stem Cells: The New Hope for Parkinson's Disease Treatment -- Compilation of References -- About the Contributors -- Index.

"Parkinson's disease is the second most common neurodegenerative disorder in the world after Alzheimer's disease. Thanks to the pioneering works of Arvid Carlson in the 20th century identifying dopamine as the main neurochemical agent involved in Parkinson's disease's onset and progress, our understanding of the neuropathology has increased. The elaboration of L-Dopa as the first pharmacological treatment approach has brought new hope for curing or at least slowing the neurodegenerative progress and the decline of motor and cognitive functions in Parkinson's disease patients. To date, imaging techniques along with genetic and biochemical tools have allowed scientists and clinicians to predict and diagnose the disease several years prior to the motor disorder's appearance. Experimental and Clinical Evidence of the Neuropathology of Parkinson's Disease sheds light on the history of Parkinson's disease as well as the recent literature on theepidemiological data worldwide including the prevalence of the disease, the morbimortality rates, and the sex dimorphism and aging components. It addresses the current neuropathological evidence of Parkinson's disease, including the latestdiscoveries in terms of neuropathology and treatments available or under clinical trials with the efficacy and limitations of each. Covering topics such as epidemiology, stem cells, and neuropathology, this premier reference source is an excellent resource for clinicians, physicians, epidemiologists, neuroscientists, microbiologists, biochemists, pharmacologists, toxicologists, medical professionals, nurses, medical students and educators, librarians, researchers, and academicians."--

ISBN: 9781668451571Subjects--Topical Terms:

1458783
Parkinson's disease
--Pathogenesis.Index Terms--Genre/Form:

554714
Electronic books.

LC Class. No.: RC382 / .E863 2023e

Dewey Class. No.: 616.833

National Library of Medicine Call No.: WL359

Experimental and clinical evidence of the neuropathology of Parkinson's disease
LDR:04546nam a2200265 a 4500 001 1136311
006 m d
007 cr nn muauu
008 241218s2023 pau fob 001 0 eng d
020 $a 9781668451571 $q (ebook)
020 $a 1668451565 $q (hardcover)
020 $a 9781668451564 $q (print)
035 $a (OCoLC)1393187775
035 $a 00294328
040 $a CaBNVSL $b eng $c CaBNVSL $d CaBNVSL
041 0 $a eng
050 4 $a RC382 $b .E863 2023e
060 4 $a WL359
082 0 4 $a 616.833 $2 23
245 0 0 $a Experimental and clinical evidence of the neuropathology of Parkinson's disease $h [electronic resource] / $c Ahmed Draoui, Omar El Hiba, Arumugam R. Jayakumar, editors.
260 $a Hershey, Pennsylvania : $b IGI Global, $c 2023.
300 $a 1 online resource (xxvii, 447 p.)
504 $a Includes bibliographical references and index.
505 0 $a Preface -- Chapter 1. History and Epidemiology of Parkinson's Disease -- Chapter 1. Epidemiology of Parkinson's Disease: An Updated Overview -- Chapter 2. Sympatomatology and Diagnosis of Parkinson's Disease -- Chapter 2. Symptomatology and Clinical Features of Parkinson's Disease -- Chapter 3. Non-Motor Symptoms in Parkinson's Disease: The Other Side of the Disease -- Chapter 4. Diagnosing Methods of Parkinson's Disease: Revolutionary Techniques -- Chapter 5. Diagnostic Biomarkers of Parkinson's Disease -- Chapter 3. Neuropathology of Parkinson's Disease -- Chapter 6. Neuropathology of Parkinson's Disease: An Update of the Recent Findings -- Chapter 7. Clinical and Experimental Evidence of Cirrhosis-Related Parkinsonism -- Chapter 4. Etiologies and Risk Factors of Parkinson's Disease -- Chapter 8. Parkinson's Disease: Clinical Manifestations and Risk Factors -- Chapter 9. Sex Dimorphism and Parkinson's Disease: What We Learned -- Chapter10. An Overview of the Genetics of Parkinson's Disease -- Chapter 11. Pesticide Exposure as a Risk Factor for Parkinson's Disease -- Chapter 12. Impact of Hydrocarbon Exposure on the Risk of Parkinson's Disease -- Chapter 5. Management of Parkinson's Disease: Pharmacological and Non-Pharmacological Treatments -- Chapter 13. Pharmacological Treatments of Parkinson's Disease: Preventing and Curing Approaches -- Chapter 14. Parkinson's Disease Related to Food and Nutrition: WhatWe Learned -- Chapter 15. Chitosan and Its Derivatives as Potential Neuro-Protective Agents for the Treatment of Parkinson's Disease -- Chapter 16. Effects of Physical Activity on Pakinson's Disease Patients -- Chapter 17. Potential Role of Probiotics and Fecal Microbiota Transplantation in the Treatment of Parkinson's Disease -- Chapter 18. Stem Cells: The New Hope for Parkinson's Disease Treatment -- Compilation of References -- About the Contributors -- Index.
520 3 $a "Parkinson's disease is the second most common neurodegenerative disorder in the world after Alzheimer's disease. Thanks to the pioneering works of Arvid Carlson in the 20th century identifying dopamine as the main neurochemical agent involved in Parkinson's disease's onset and progress, our understanding of the neuropathology has increased. The elaboration of L-Dopa as the first pharmacological treatment approach has brought new hope for curing or at least slowing the neurodegenerative progress and the decline of motor and cognitive functions in Parkinson's disease patients. To date, imaging techniques along with genetic and biochemical tools have allowed scientists and clinicians to predict and diagnose the disease several years prior to the motor disorder's appearance. Experimental and Clinical Evidence of the Neuropathology of Parkinson's Disease sheds light on the history of Parkinson's disease as well as the recent literature on theepidemiological data worldwide including the prevalence of the disease, the morbimortality rates, and the sex dimorphism and aging components. It addresses the current neuropathological evidence of Parkinson's disease, including the latestdiscoveries in terms of neuropathology and treatments available or under clinical trials with the efficacy and limitations of each. Covering topics such as epidemiology, stem cells, and neuropathology, this premier reference source is an excellent resource for clinicians, physicians, epidemiologists, neuroscientists, microbiologists, biochemists, pharmacologists, toxicologists, medical professionals, nurses, medical students and educators, librarians, researchers, and academicians."-- $c Provided by publisher.
650 0 $a Parkinson's disease $x Pathogenesis. $3 1458783
650 0 $a Nervous system $x Diseases. $3 581546
655 4 $a Electronic books. $2 local $3 554714
700 1 $a Jayakumar, Arumugam R. $3 1458780
700 1 $a Hiba, Omar El. $3 1458781
700 1 $a Draoui, Ahmed, $d 1986- $3 1458782
710 2 $a IGI Global. $3 805187
856 4 0 $u http://services.igi-global.com/resolvedoi/resolve.aspx?doi=10.4018/978-1-6684-5156-4